An 8-day Open-label, Multiple-dose, Multicenter Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age.
Phase of Trial: Phase I/II
Latest Information Update: 22 Apr 2013
At a glance
- Drugs Aliskiren (Primary)
- Indications Hypertension
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis
- 31 Mar 2012 Planned number of patients changed from 36 to 39 as reported by European Clinical Trials Database record.
- 20 Jun 2011 Safety and preliminary efficacy results presented at the 21st European Meeting on Hypertension.
- 02 Jun 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History